Regulation (EU) 2017/2101 of the European Parliament and of the Council [6] provides the framework for the exchange of information on new psychoactive substances and for a risk assessment procedure based on an initial report and risk assessment report drawn up to evaluate whether a new psychoactive substance poses severe public health and social risks.
Le Rialachán (AE) 2017/2101 ó Pharlaimint na hEorpa agus ón gComhairle [6], foráiltear do chreat faoina bhféadfar faisnéis a mhalartú maidir le substaintí sícighníomhacha nua agus foráiltear do nós imeachta measúnaithe riosca bunaithe ar thuarascáil tosaigh agus ar thuarascáil ar an measúnú riosca arna ndréachtú lena mheas an ngabhann rioscaí tromchúiseacha don tsláinte phoiblí agus rioscaí tromchúiseacha sóisialta le substaint shícighníomhach nua.